Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   30/06/2025
25,84 USD (+0,31%)
(+0,31%)   30/06/2025

13 mei 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference · Persbericht

8 mei 2025 · Nektar Therapeutics Reports First Quarter 2025 Financial Results · Persbericht

2 mei 2025 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets · Persbericht

20 maart 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

12 maart 2025 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

6 maart 2025 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets · Persbericht

3 september 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Nektar Therapeutics Reports Second Quarter 2024 Financial Results · Persbericht

2 augustus 2024 · Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets · Persbericht

12 juni 2024 · Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 · Persbericht

31 mei 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

9 mei 2024 · Nektar Therapeutics Reports First Quarter 2024 Financial Results · Persbericht

3 mei 2024 · Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets · Persbericht

22 maart 2024 · Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

5 maart 2024 · Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata · Persbericht

4 maart 2024 · Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results · Persbericht

4 maart 2024 · Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX · Persbericht

28 februari 2024 · Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference · Persbericht

27 februari 2024 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets · Persbericht

4 januari 2024 · Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA · Persbericht

Mijn selecties